The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 352:1368-1370 March 31, 2005 Number 13
NextNext

Warfarin, Aspirin, and Intracranial Vascular Disease
Walter J. Koroshetz, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Chimowitz, M. I.
-PubMed Citation
The Warfarin–Aspirin Symptomatic Intracranial Disease (WASID) Trial, funded by the National Institute of Neurological Disorders and Stroke and reported by Chimowitz et al.1 in this issue of the Journal, was a careful comparison of these two therapies in patients with cerebrovascular events attributed to intracranial atherosclerosis. The WASID Trial, in concert with other, smaller studies,2,3 clearly shows that symptomatic intracranial atherosclerotic stenosis is a marker of extremely aggressive vascular disease. Ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke occurred within two years in approximately 22 percent of the patients, whether they were treated with high-dose aspirin . . . [Full Text of this Article]


Source Information

From the Stroke Service, Massachusetts General Hospital, Boston.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.